The future of hemp and cannabis derivatives is currently hanging by a thread: on one hand, increasing restrictions on the use of CBD and other cannabinoids in food products; on the other, greater recognition of their medicinal uses, but within a much stricter framework. For adult consumers in France and Europe, this evolution may seem contradictory. In reality, it primarily reflects a desire on the part of authorities to better distinguish between what constitutes pleasure, well-being, food, and medicine.
In 2026, several strong signals confirmed this trend. In France, the announced withdrawal of CBD-containing foods deemed illegal reignited the debate. At the European level, the EFSA, EUDA, the Commission, and national institutions all reiterate the same fundamental point: plant-derived products do not all have the same status, nor are they subject to the same safety requirements. So, what future lies ahead for plant-derived products, caught between food bans and medical regulations?
A regulatory turning point in France in 2026
In May 2026, the French Ministry of Agriculture announced the withdrawal from the market of food products containing CBD deemed illegal. This marked a real turning point, as it was no longer just a theoretical debate between professionals and authorities: it was now a question of concrete action on products available on store shelves or online. For many players in the sector, this confirms that tolerance surrounding certain food formats is reaching its limits.
The ministerial statement relies in particular on the position of the EFSA, which confirmed in February 2026 that safety gaps persist for the food uses of CBD. In other words, even before discussing marketing or popularity, the central issue remains that of evidence. As long as toxicological, metabolic, and clinical data are not deemed sufficient, food marketing remains precarious.
This approach also aligns with an existing administrative position in France. According to the analysis cited by MILDECA, the other parts of the plant, CBD, and other cannabinoids are considered to lack sufficient historical consumption for the food market. Therefore, in principle, they must be authorized before being sold. This immediately places a large proportion of -derived products plant in the "novel food" category.
The crux of the problem: food or medicine?
The distinction between food and medicine remains central to the issue in 2026. EUDA reiterated in April that a food cannot claim therapeutic effects. As soon as a product claims to prevent, treat, or alleviate an illness, it potentially falls under the category of medicine. And at that point, the level of requirements changes completely: marketing authorization, manufacturing controls, monitoring, and a medical framework become the norm.
This distinction isn't just a matter of labeling. It shapes the entire future of the sector. A plant-derived product sold as a food item, wellness oil, or functional preparation isn't assessed in the same way as a substance used in a medical protocol. European authorities want to prevent the same extract from circulating freely as food while implicitly being presented as a therapeutic solution.
EUDA also points out that a health claim on a food product must be authorized under the Health Claims Regulation. This means that physiological benefits cannot simply be suggested without a solid regulatory basis. For CBD and other cannabis extracts, the issue of legal status therefore depends as much on the formulation as on the claimed use. It is precisely this ambiguity that is fueling current market tensions.
Why CBD foods remain under pressure
The pressure surrounding CBD-containing foods doesn't stem solely from a strict interpretation of the regulations. It also rests on concrete health concerns. The MILDECA (Interministerial Mission for the Fight against Drugs and Addictive Behaviors) specifically refers to the risk of THC exposure, relying on the acute reference dose established by the EFSA (European Food Safety Authority). Even when a product is marketed as "CBD," the question of residual THC levels, their variability, and their potential accumulation remains a sensitive one.
Recent scientific literature supports this view. A review published in 2026 highlights persistent uncertainties surrounding cannabinoid-based food products: actual dosage, purity, potential liver effects, drug interactions, and specific risks for certain vulnerable populations. This particularly concerns individuals taking multiple medications, those with liver problems, and consumers who are poorly informed about actual concentrations.
In this context, the authorities believe that mere commercial hype cannot replace a demonstration of safety. This is why the "novel food" filter continues to play a central role at the European level. As long as a cannabinoid extract does not clearly pass the evaluation and authorization stages, its future as a food ingredient remains highly uncertain.
“Novel food” as a European lock
In 2026, the EFSA published a safety opinion on a CO₂ extract of Cannabis sativa as a “novel food.” The opinion of March 30 concerns an hemp extract subject to the European regulation on novel foods. This type of procedure clearly demonstrates that Europe does not necessarily prohibit all derivatives of the plant in principle, but that it requires a robust, standardized, and scientifically defensible dossier.
The message is clear: controversial cannabinoid extracts will not be able to establish a lasting presence on the food market without formal approval. The European food catalogue and the work surrounding "novel foods" now serve as a major filter before products can be placed on the market. This approach favors operators capable of investing in compliance, laboratory testing, and traceability, rather than opportunistic models.
The underlying regulatory trend in the EU therefore remains a clear separation between authorized hemp-derived food products and cannabinoid extracts, the status of which remains a subject of debate. At the same time, agricultural policy continues to distinguish industrial hemp from other uses of cannabis, notably through licensing requirements for certain imports. This serves as a reminder that the plant can fall under agricultural, food, health, and pharmaceutical regulations.
Legal recourse exists, but uncertainty persists
In July 2026, the Council of State was petitioned for an interim injunction against the ban on the sale of food products containing CBD. The ruling addresses the challenge to the 2026 national control plan and the implications of the "Novel Food" classification. This appeal demonstrates that the debate is far from over. Some professionals believe that certain administrative interpretations go too far or lack proportionality.
However, legal challenges alone are not enough to immediately create a stable market. Even if certain measures are debated in court, the overall framework remains dominated by the principle of regulatory precaution. In practice, this means that sellers, manufacturers, and consumers still operate in a constantly evolving environment, where legal and documentary compliance becomes essential.
This period of uncertainty also fosters professionalization within the sector. Reputable players have every incentive to precisely document the origin of the hemp, cannabinoid profiles, contaminant analyses, THC levels, and the legal status of each product. For consumers, this reinforces the importance of choosing laboratory-tested, transparent products that are clearly positioned outside the realm of vague therapeutic claims.
Medical supervision is gaining ground
While food uses face more obstacles, medical uses, on the contrary, seem to be gaining institutional legitimacy. But this legitimacy comes with significantly stricter control. The prevailing idea by 2026 is simple: if a plant derivative has genuine therapeutic potential, it must then be evaluated, prescribed, authorized, and monitored like a medicine.
This movement is not limited to Europe. In the United States, in April 2026, the Department of Justice eased certain controls on medical marijuana under Schedule III, for products included in a drug approved by the FDA or subject to a state license for medical use. At the same time, the FDA continues to reiterate that it closely monitors cannabis products and derivatives, including CBD, and that it prohibits the marketing of certain active substances in foods or supplements when they are already incorporated into certain approved drugs.
Canada provides another interesting indicator. Health Canada is publishing detailed tables on medical cannabis by product type in 2026, demonstrating that a structured medical market can coexist with strong restrictions on other uses. The international message is therefore consistent: a therapeutic future exists, but within an ecosystem of authorization, monitoring, and enhanced medical accountability.
The sensitive case of new cannabinoids
The debate isn't limited to traditional CBD. The 2026 scientific review highlights that derivatives like Δ8-THC, HHC, and related compounds present additional challenges. Their regulation is often inconsistent across countries, while toxicological data remains limited. This significantly complicates their commercial future, especially when incorporated into edible products or marketed in overly appealing ways.
For the authorities, these molecules present several risk factors: a lack of scientific data, sometimes complex processing methods, poorly understood pharmacological profiles, and difficulty in properly informing consumers. In this context, it is likely that Europe will continue to adopt a cautious, even restrictive, approach, especially for food products and similar items.
For the market, this means that a sustainable future will likely require greater standardization, toxicology, analytical control, and legal clarity. New cannabinoids will probably not be able to develop smoothly based on mere fads. The operators who survive will be those capable of anticipating tomorrow's requirements, not just today's demand.
Towards a more transparent European harmonization?
In 2026, the European institutional debate is also shifting towards greater harmonization of hemp regulations. The European Parliament indicates that the Commission wants to reduce the differences between Member States regarding production and marketing. This is a major issue, as national disparities create uncertainty for both businesses and consumers.
Harmonization will not necessarily mean general liberalization. On the contrary, it could reinforce a two-tiered system: clearly defined industrial hemp on one side, certain finished products subject to specific regulations on the other, and cannabinoids for therapeutic purposes within the medical field. This clarification would nevertheless be positive, as it would reduce the gray areas that currently fuel confusion.
For adult consumers in France and Europe, this scenario would undoubtedly be the healthiest. It would allow for a clearer understanding of which -derived products plant fall under the category of non-food wellness products, which are authorized under specific conditions, and which should remain reserved for medical supervision. In the long run, trust is always built more effectively on clear regulations than on vague tolerances.
In light of the developments projected for 2026, the trajectory appears increasingly clear: plant-derived products are heading towards a dual future. On the one hand, food products containing CBD and cannabinoids remain under significant pressure, facing bans, market withdrawals, and the requirement for prior authorization. On the other hand, medical uses are gaining legitimacy, but only under stricter prescription, authorization, and oversight.
For both consumers and professionals, the real challenge is no longer simply following trends, but understanding the framework. In the coming years, value will undoubtedly be concentrated on compliance, analytical quality, transparency, and sound regulatory positioning. Clearly, the future of plant-derived products will not be one of a completely free market, but rather one of a more mature, more regulated, and, hopefully, more reliable sector for everyone.
